Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio Inc., a biopharma company based in South San Francisco, focused on the discovery and development of disease-modifying neuroprotective drugs, today announced the publication of research elucidating the molecular details of a conserved, NAD-dependent inhibitory mechanism that results in highly potent small molecule inhibitors of...

Click to view original post